NBY
Price
$3.68
Change
-$0.54 (-12.80%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
21.72M
PALI
Price
$0.63
Change
-$0.00 (-0.00%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
5.84M
Interact to see
Advertisement

NBY vs PALI

Header iconNBY vs PALI Comparison
Open Charts NBY vs PALIBanner chart's image
NovaBay Pharmaceuticals
Price$3.68
Change-$0.54 (-12.80%)
Volume$22.97K
Capitalization21.72M
Palisade Bio
Price$0.63
Change-$0.00 (-0.00%)
Volume$1.5K
Capitalization5.84M
NBY vs PALI Comparison Chart in %
Loading...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NBY vs. PALI commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBY is a StrongBuy and PALI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (NBY: $3.73 vs. PALI: $0.63)
Brand notoriety: NBY and PALI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NBY: 105% vs. PALI: 173%
Market capitalization -- NBY: $21.72M vs. PALI: $5.84M
NBY [@Biotechnology] is valued at $21.72M. PALI’s [@Biotechnology] market capitalization is $5.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBY’s FA Score shows that 2 FA rating(s) are green whilePALI’s FA Score has 1 green FA rating(s).

  • NBY’s FA Score: 2 green, 3 red.
  • PALI’s FA Score: 1 green, 4 red.
According to our system of comparison, NBY is a better buy in the long-term than PALI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBY’s TA Score shows that 5 TA indicator(s) are bullish while PALI’s TA Score has 4 bullish TA indicator(s).

  • NBY’s TA Score: 5 bullish, 5 bearish.
  • PALI’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, NBY is a better buy in the short-term than PALI.

Price Growth

NBY (@Biotechnology) experienced а +109.55% price change this week, while PALI (@Biotechnology) price change was -7.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBY($21.7M) has a higher market cap than PALI($5.84M). NBY has higher P/E ratio than PALI: NBY (1.62) vs PALI (0.02). NBY YTD gains are higher at: 602.163 vs. PALI (-61.655). NBY has higher annual earnings (EBITDA): -7.05M vs. PALI (-11.83M). PALI (5.42M) and NBY (5.34M) have equal amount of cash in the bank . PALI has less debt than NBY: PALI (338K) vs NBY (1.04M). NBY has higher revenues than PALI: NBY (9.78M) vs PALI (0).
NBYPALINBY / PALI
Capitalization21.7M5.84M372%
EBITDA-7.05M-11.83M60%
Gain YTD602.163-61.655-977%
P/E Ratio1.620.029,171%
Revenue9.78M0-
Total Cash5.34M5.42M99%
Total Debt1.04M338K308%
FUNDAMENTALS RATINGS
NBY vs PALI: Fundamental Ratings
NBY
PALI
OUTLOOK RATING
1..100
3450
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
12100
PRICE GROWTH RATING
1..100
3493
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PALI's Valuation (28) in the null industry is in the same range as NBY (49) in the Biotechnology industry. This means that PALI’s stock grew similarly to NBY’s over the last 12 months.

PALI's Profit vs Risk Rating (100) in the null industry is in the same range as NBY (100) in the Biotechnology industry. This means that PALI’s stock grew similarly to NBY’s over the last 12 months.

NBY's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for PALI (100) in the null industry. This means that NBY’s stock grew significantly faster than PALI’s over the last 12 months.

NBY's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for PALI (93) in the null industry. This means that NBY’s stock grew somewhat faster than PALI’s over the last 12 months.

NBY's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for PALI (100) in the null industry. This means that NBY’s stock grew significantly faster than PALI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBYPALI
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 15 days ago
86%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NX20.910.82
+4.08%
Quanex Building Products Corp
XGN9.830.15
+1.55%
Exagen
ROLR2.84N/A
+0.03%
High Roller Technologies Inc
POR42.66-0.07
-0.16%
Portland General Electric Company
CMG41.41-0.38
-0.91%
Chipotle Mexican Grill

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NBY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
+57.46%
CDTX - NBY
93%
Closely correlated
+2.36%
NCNA - NBY
93%
Closely correlated
-5.92%
TAOX - NBY
91%
Closely correlated
-3.50%
RNAC - NBY
91%
Closely correlated
-2.44%
AGEN - NBY
90%
Closely correlated
+0.70%
More

PALI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PALI has been closely correlated with CDTX. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PALI
1D Price
Change %
PALI100%
-2.41%
CDTX - PALI
82%
Closely correlated
+2.36%
TAOX - PALI
81%
Closely correlated
-3.50%
NCNA - PALI
81%
Closely correlated
-5.92%
NBY - PALI
80%
Closely correlated
+57.46%
AGEN - PALI
80%
Closely correlated
+0.70%
More